Increasing SARS-CoV2 cases, hospitalizations and deaths among the vaccinated elderly populations during the Omicron (B.1.1.529) variant surge in UK

Venkata R. Emani, Vivek K. Pallipuram, Kartik K. Goswami, Kailash R. Maddula, Raghunath Reddy, Abirath S. Nakka, Sravya Panga, Nikhila K. Reddy, Nidhi K. Reddy, Dheeraj Nandanoor, Sanjeev Goswami
doi: https://doi.org/10.1101/2022.06.28.22276926

ABSTRACT

BACKGROUND There were increased SARS-CoV2 hospitalizations and deaths noted during Omicron (B.1.1.529) variant surge in UK despite decreased cases, and the reasons are unclear.

METHODS In this retrospective observational study, we analyzed reported SARS-CoV2 cases, hospitalizations and deaths during the COVID-19 pandemic in the UK. We also analyzed variables (ethnic, deprivation score vaccination disparities and pre-existing conditions) that can affect the outcomes. The vaccine effectiveness among those ≥18 years of age (August 16, 2021 to March 27, 2022) was analyzed.

RESULTS Of the total cases (n= 22,072,550), hospitalizations (n=848,911) and deaths (n=175,070) due to COVID-19 in the UK; 51.3% of cases (n=11,315,793), 28.8% of hospitalizations (n=244,708), and 16.4% of deaths (n=28,659) occurred during the Omicron variant surge. When comparing the period of February 28 - May 1, 2022 with the prior 12-weeks, we observed a significant increase in the case fatality rate (0.19% vs 0.41%; RR 2.11 [2.06-2.16], p<0.001) and the risk of hospitalizations (1.58% vs 3.72%; RR 2.36[2.34-2.38]; p<0.001). During the same period, we also observed a significant increase in the proportion of cases (23.7% vs 40.3%; RR1.70 [1.70-1.71]; p<0.001) among ≥50 years of age and hospitalizations (39.3% vs 50.3%;RR1.28 [1.27-1.30]; p<0.001) and deaths (67.89% vs 80.07%;RR1.18 [1.16-1.20]; p<0.001) among ≥75 years of age. The vaccine effectiveness (VE) for the third dose was in negative since December 20, 2021, with a significantly increased proportion of SARS-CoV2 cases hospitalizations and deaths among the vaccinated; and a decreased proportion of cases, hospitalizations, and deaths among the unvaccinated. The pre-existing conditions were present in 95.6% of all COVID-19 deaths and we also observed various ethnic, deprivation score and vaccination rate disparities that can adversely affect hospitalization and deaths among the compared groups based on the vaccination status.

CONCLUSIONS There is no discernable optimal vaccine effectiveness among ≥18 years of age, vaccinated third dose population since December 20, 2021 during the beginning of the Omicron variant surge. Pre-existing conditions, ethnicity, deprivation score, and vaccination rate disparities data need to be adjusted by the development of validated models for evaluating VE for hospitalizations and deaths. The increased proportion of cases with significantly increased risk of hospitalizations and deaths among the elderly population during the Omicron variant surge underscores the need to prevent infections in the elderly irrespective of vaccination status with uniform screening protocols and protective measures.

INTRODUCTION

Following the World Health Organization (WHO), the UK Health Security Agency (UKHSA) designated the Omicron variant (B.1.1.529) of the SARS-CoV2, the virus that causes COVID-19, as a variant of concern on November 27, 20211–3. The Omicron variant spread rapidly across the United Kingdom (UK) and became a predominant strain with 365,375 confirmed cases as of December 23, 20214, 5. UK reported a total of 11.3 million SARS CoV2 cases during the Omicron variant surge in twenty-one weeks as of May 1, 2022 with a majority of the newly confirmed infections of Omicron variant lineages (B.1.1.529 and B.1.1.529.BA.2)6, 7.

The UK COVID-19 vaccination program started in December 2020, with two doses of either mRNA-based vaccines (BNT162b2 and mRNA-1273) or adenoviral vector-based vaccine (ChAdOx1 nCoV-19). Approximately 73.9% of the ≥50 years old population were vaccinated by May 2, 2021 during the beginning of the Delta variant (B.1.617.2) surge8.

After the initial approval the third dose (booster) to only immunocompromised population, the UK authorities approved the third dose to ≥50 years old general population on September 14, 2021 to be administered no sooner than within six months after the primary course9, 10. The third dose vaccination was subsequently expanded in UK to over 18 years old population on November 29, 2021 and changed the booster timing to no sooner than three months after the primary course due to changing risk posed by Omicron variant11. The UK government later announced the fourth dose (booster) in March 2022 12, 13.

While the vaccine immunity was reported waning during the Delta variant surge elsewhere, the initial Public Health England reported a good vaccine effectiveness with two doses of BNT162b2 and ChAdOx1 nCoV-19 vaccine among those with the delta variant (B.1.617.2)14–17. A later study reported waning of effectiveness for symptomatic infections with Delta variant, but limited waning in effectiveness against COVID-19 related hospitalizations and deaths18. During this time, the UK technical briefings also showed a growing problem of breakthrough infection in confirmed Delta variant cases among the ≥50 years age group with 75.3% of breakthrough cases (63.5% of hospitalizations and 67.0% of deaths) as of September 12, 202119–21. Similarly, the weekly vaccine surveillance reports also show a trend of increased cases in the vaccinated third booster population than the unvaccinated population during the Omicron variant surge22. These reports highlight an alarming trend of increased hospitalizations and deaths among the vaccinated third dose population until they stopped reporting the underlying data after March 27, 202222. The UK COVID-19 dashboard is also reporting a relatively higher number of daily hospitalizations and deaths during the later period of the Omicron variant surge in March-April 2022, despite substantially lower cases reported6.

In this retrospective observational study, the changing pattern of SARS-CoV2 cases, hospitalizations and deaths among various age groups during the Omicron variant surge relative to earlier surges was analyzed. We also analyzed SARS-CoV2 cases, hospitalizations and deaths among ≥18 years old population based on the vaccination status during the Omicron variant surge.

METHODS

STUDY DESIGN

In this retrospective observational study, we analyzed the nationwide available data of the confirmed SARS-CoV2 cases, hospitalizations and deaths in the UK from the beginning of the COVID-19 pandemic until May 1, 2022. The vaccine effectiveness (VE) was calculated based on the data from the UK vaccine surveillance reports and the UK technical briefings until March 27, 2022. We also analyzed the data on racial ethnicity, pre-existing conditions, Indices of Multiple Deprivation (IMD) score and adaptation of SARS-CoV2 vaccination among racial ethnic groups.

DATA SOURCES AND ANALYSIS

Total UK SARS-COV2 cases, hospitalizations and deaths

Analysis of the SARS-CoV2 cases (specimen date), SARS-CoV2 hospitalizations and SARS-CoV2 deaths (deaths within 28 days of positive test by the data of deaths) in the UK was performed from the beginning of the pandemic until May 1, 2022 using the data from UK corona virus dashboard6. The case fatality rate (CFR) was calculated as the percentage of SARS-CoV2 deaths of the reported cases, The risk of hospitalizations (RH) was calculated as the percentage of SARS-CoV2 hospitalizations of the reported cases (Equation 1). The hospitalization death rate (HDR) was calculated as the percentage of SARS-CoV2 deaths of the reported hospitalizations (Equation 2). The various periods of the pandemic chosen for the analysis was based on the starting period of the surges and changing pattern of outcomes from February 28, 2022 during the latter part of the Omicron variant surge until May 1, 2022 study period. Embedded Image

Embedded Image

SARS-COV2 cases, hospitalizations among the age groups in England and SARS-CoV2 deaths in England and Wales

Cases

We analyzed SARS-CoV2 cases reported under pillar 1 (public health laboratories and hospitals) and pillar 2 (community testing) in England among various age groups (0-19, 20-29, 30-49, 50-69, ≥50, ≥70 and ≥80 years of age) from September 28, 2020 to May 1, 2022 using the data from National Flue and COVID-19 surveillance reports (2020-2021 season and 2021-2022 season)8, 23.

Hospitalizations

We examined the daily hospitalizations in England among various age groups (0-17, 18-34, 35-54, 55-64, ≥65-74 and ≥75 years of age) from October 12, 2020 to May 1, 2022 using the National Health Services (NHS) database of COVID-19 hospital activity24.

Deaths

We analyzed the weekly SAVRS-CoV2 deaths among various age groups (0-19, 20-29, 30-49, 50-69, ≥70-74, ≥50 and ≥75 years of age) in England and Wales from the beginning of the pandemic in March 2020 to May 1, 2022 using the UK Office for National Statistics dataset25. We compared the weekly SARS-CoV2 deaths among various age groups during each surge with prior surges .

We tabulated and analyzed the changing pattern of cases, hospitalizations and deaths during various surges.

Analysis of the factors known to impact the SARS-CoV2 outcomes

Pre-existing conditions among COVID-19 deaths and COVID-19 deaths among ethnic groups in England: The National Health Services weekly data of COVID-19 deaths archives was used to analyze the pre-existing conditions among COVID-19 deaths in various age groups26.

SARS-CoV2 cases, hospitalizations and deaths among ethnic groups and deprived populations based on IMD score: SARS-CoV2 cases (pillar 1 and pillar 2) per 100, 000 population among various ethnic groups (from June 29, 2020 to May 1, 2022), SARS-COV-2 hospitalizations (excluding ICU/HDU), SARS-CoV2 admission to ICU/HDU units (March 16, 2020 to May 1, 2022), SARS-CoV2 pillar 1 and 2 cases and SARS-CoV2 deaths per 100, 000 population among population-based on Indices of Multiple Deprivation (from June 27, 2020 to April May 1, 2022) were tabulated with weekly data from the National Flu and COVID-19 surveillance reports8. The IMD quintile 1 and decile 1 are considered the most deprived and quintile 5 and decile 10 are the least deprived8.

Vaccine uptake among racial minorities

The weekly vaccine uptake data among various ethnic groups was analyzed for the period ending May 1, 20228.

Vaccination data

The National Immunization Management System (NIMS) vaccination data since the beginning of the vaccination program in December 2020 which was published weekly in the National Flu and COVID-19 surveillance reports was used to calculate the vaccinated and unvaccinated population among age groups for a specified period of vaccine effectiveness8. The SARS-CoV2 cases, hospitalizations (cases presenting to emergency care within 28 days of a positive test resulting in overnight inpatient admission) and deaths (within 28 days of a positive COVID-19 test) among various age groups (published weekly) with an aggregate of 4 weeks data since August 16, 2021 to March 27, 2022 periods (for the third dose since December 20, 2021) in the COVID-19 vaccine surveillance reports was used in our data analysis 22. The Public Health England technical briefings data of SARS-CoV2 cases, hospitalizations and deaths among the confirmed cases of Delta variant was used for analysis during the period ending June 21, 2021 to September 12, 2021 (included in supplemental appendix)27.

The UK Health Security Agencies COVID-19 vaccine surveillance reports did not publish the third dose cases, hospitalizations and deaths until December 19, 2021. We used ≥18 years, pillar 2 cases published by the UKHSA in between November 27, 2021 to January 12, 2022 periods to calculate the vaccine effectiveness of the third dose28.

We used over 18 years age groups for vaccine effectiveness because the younger age population was excluded in the randomized controlled trials initially and over 18 years of age was chosen in a recent UKHSA publication28–31. We also analyzed the vaccine effectiveness among over 50 years population for infections. The SARS-CoV2 events (cases, hospitalizations, and deaths) tested positive with the specimen date ≥14 days post second dose are considered vaccinated with two doses; the events ≥14 days after receiving third dose are considered vaccinated with the third dose, and the events post one dose without additional doses of vaccination are considered one dose22.

STATISTICAL ANALYSIS

We conducted the statistical analysis using the R software, version 4.1.3. We compared the cases, hospitalizations, and deaths among the various age groups between the surges to determine the changing pattern of cases, infections, and deaths during the course of the pandemic. Among those experiencing the event (cases, hospitalizations or death), the proportion of change (Δ) compared to the immediate prior period in a particular age group (increased or decreased) was calculated as the relative risk (RR), the 95% confidence interval, and the p-value.

We used the weekly published National Immunization Management System (NIMS) vaccination data to calculate the population for each age group for vaccine effectiveness8. We obtained the number of cases, hospitalizations, and deaths from the vaccine surveillance reports, and the data of these outcomes linked to the NIMS database22. The incidence rate was calculated as a number of SARS-CoV2 infections, hospitalizations or deaths per 100,000 population for each studied group. The incidence rate ratio (IRR) was calculated among the compared groups. The partially vaccinated (received 1 dose), vaccinated with two doses and the third booster were compared with the unvaccinated for the VE calculations. Vaccine effectiveness was calculated as (1-IRR) x 100. We performed the two-proportions test with continuity correlation (henceforth two-proportions test) to determine whether the proportion of cases, hospitalizations, and deaths among the vaccinated population are significantly higher than the unvaccinated population.

RESULTS

United Kingdom SARS-CoV2 cases, SARS-CoV2 hospitalizations and SARS-CoV2 deaths (Figure 1)

There was a total of SARS-CoV2 cases (n=22,072,550); hospitalizations (n=848,911) and deaths (n=175,070) reported in the UK during the entire pandemic as of May 1, 2022. The majority of cases (51.3%; n=11,315,793), the majority of hospitalizations (28.8%; n=244,708), and the second-highest percentage of deaths (16.4%; n=28,659) occurred in the twenty-one weeks period during the Omicron variant surge as per our study (December 6, 2021 to May 1, 2022).

Figure 1:
Figure 1:

Total SARS-CoV2 cases, hospitalizations, and deaths in UK during the entire COVID-19 pandemic until May 1, 2022. The graph illustrates the increasing risk of the hospitalization (RH) and case fatality rate (CFR) during the latter part of the Omicron variant surge. The RH and CFR significantly increased during the latter part of the Omicron variant surge, (February 27-May 1, 2022) mainly driven by increased hospitalizations and deaths despite the lower number of cases. The changes in the hospitalization death rate (HDR) during the various time periods was also illustrated.

The case fatality rate (CFR) of 13.2% and risk of hospitalizations (RH) of 41.4% were highest during the first wave (February 24 - August 16, 2020). During the Alpha variant surge, the CFR was 2.41% with an RH of 8.42%. The CFR and RH decreased to 0.29% and 2.28%, respectively during the Delta variant surge and the lowest CFR of 0.25% and RH of 2.16% were observed during the Omicron variant surge. The CFR (0.19% vs 0.41%; RR 2.11, 95% CI 2.06-2.16, p<0.001) and RH (1.58% vs 3.72%; RR 2.36, 95% CI 2.34-2.38; p<0.001) significantly increased during the 9 weeks period ending May 1, 2022 in the latter part of the Omicron variant surge compared to the earlier 12 weeks.

SARS-CoV2 cases, SARS-CoV2 Hospitalizations (in England) and SARS-CoV2 deaths (England and Wales) among age groups (Figures 2a-c; Tables S1a-c)

Of the reported total SARS-CoV2 cases in England, analysis of cases among various age groups showed a significantly increased percentage of cases among ≥50 years age group during the initial part of the Omicron variant surge compared to immediate prior period (21.9% vs 23.7%; RR 10.07; 95% CI 1.07-1.08);p<0.001) and during the latter part of Omicron variant surge (23.7% vs 40.3%; RR 1.70;95% CI 1.70-1.71;p<0.001) compared to immediate prior period as shown on the Table S1a, particularly among ≥70 years age of age. During the same periods of the reported total SARS-CoV2 hospitalizations in England, there were significantly increased hospitalizations among ≥75 years age group during the initial (30.8% vs 39.2%; RR 1.27;95% CI 1.25-1.29;p<0.001) and the latter part of Omicron variant surge (39.2% vs 50.3%;RR 1.28;95% CI 1.27-1.30;p<0.001) compared to immediate prior periods. The reported total SARS-CoV2 deaths in England and Wales during this time revealed significantly increased deaths during the initial part of the Omicron variant surge among 70-74 years (11.58% vs 16.02%; RR1.38;95%CI 1.30-1.47;p<0.001) and ≥75 years age group (59.33% vs 67.89%; RR1.14;95%CI 1.12-1.17;p<0.001) compared to immediate prior periods. During the latter part of Omicron variant surge ≥75 years age group have significantly increased deaths (67.89% vs 80.07%; RR1.18;95%CI 1.16-1.20;p<0.001) of the reported total SARS-CoV2 deaths and 70-74 years age group showed significantly decreased deaths (16.02% vs 7.69%; RR 0.48;95% CI 0.44-0.52);p<0.001). The proportion of hospitalizations and deaths significantly decreased in <75 years of age with associated decreased cases in <50 years of age during the latter part of Omicron variant surge of the reported total events.

Figure 2a:
Figure 2a:

SARS-CoV2 cases (pillars 1 and 2) in England among various age groups in England from September 28, 2020 to May 1, 2022. The number of cases during the various surges is shown on the top panel for each age group (n=; %) and the percentage of two weekly cases among each age group is shown on the graph. As shown, there was an increased percentage of cases noted among ≥50 years of age groups of the total events compared to immediate prior period (that was noted to be statistically significant as shown in Table S1a) during the latter part of the Omicron variant surge during the February 28-May 1, 2022 period. The percentage of cases among the <50 years of age groups significantly decreased during the same period as shown in Table S1a.

Figure 2b:
Figure 2b:

SARS-CoV2 hospitalization in England among various age groups in England from October 12, 2020 to May 1, 2022. The number of hospitalizations during the various surges is shown on the top panel for each age group (n=; %) and the percentage of weekly hospitalizations among each age group is shown on the graph. As shown, there was an increased percentage of hospitalizations noted among ≥75 years of age groups of the total events compared to immediate prior period (that was noted to be statistically significant as shown in Table S1b) during the latter part of the Omicron variant surge during the February 28-May 1, 2022 period. The percentage of hospitalizations among the <55 years of age groups significantly decreased during the same period as shown in Table S1b.

Figure 2c:
Figure 2c:

SARS-CoV2 deaths in England and Wales among various age groups from February 24, 2020 to May 1, 2022. The number of deaths during the various surges is shown on the top panel for each age group (n=; %) and the percentage of weekly deaths among each age group is shown on the graph. As shown, there was an increased percentage of deaths noted among ≥75 years of age groups of the total events compared to immediate prior period (that was noted to be statistically significant as shown in Table S1c) during the latter part of the Omicron variant surge during the February 28-May 1, 2022 period. The percentage of deaths among the <75 years of age groups significantly decreased during the same period as shown in Table S1c.

SARS-CoV2 cases, hospitalizations, ICU admissions and deaths among ethnic groups and deprived populations based on IMD score in England (Figures 3a-e)

SARS-CoV2 cases and hospitalizations per 100,000 were highest in ethnic minorities than in the white ethnic group during and prior to the Alpha variant surge, the initial part of the Delta and Omicron variant surges. The case rates and hospitalization rates among the white ethnic group increased during the latter part of the Delta variant surge and the latter part of the Omicron variant surge from February 28-May 1, 2022. However, the white ethnic group have lower ICU/HDU admission rates during the entire pandemic since March 2020. The cases per 100,000 population among the most deprived (IMD score) have higher case rates than the least deprived during the Alpha and initial part of Delta and Omicron variant surges, while the least deprived have higher rates of cases during the latter part of Delta and particularly during the latter part of Omicron variant surge (February 28-May 1, 2022). However, the death rate among the most deprived is higher than the least deprived all throughout the pandemic, although the gap is narrowing during the latter part of the Omicron variant surge.

Figure 3a:
Figure 3a:

Weekly SARS-CoV2 cases (pillars 1 and 2) per 100,000 population among various ethnic groups in England from June 29, 2020 to May 1, 2022. As shown in the graph, racial minorities have higher infection rates period to and during the alpha variant surge, during the initial part of the Delta and Omicron variant surges than the white ethnic group. During the latter part of the Delta and Omicron variant surges, the white ethnic group have higher infection rates than other minorities.

Figure 3b:
Figure 3b:

Weekly SARS-CoV2 hospitalizations per 100,000 population among various ethnic groups in England from March 16, 2020 to May 1, 2022. As shown the graph, racial minorities (black, Asian, mixed and other) have higher hospitalization rates during the First wave, the Alpha variant surge, and during the Delta variant surge. During the initial part of the Omicron variant surges racial minorities (black and other) have higher rates of hospitalization than the white ethnic group. During the latter part of the Omicron variant surges, the white ethnic group hospitalization rates increased.

Figure 3c:
Figure 3c:

Weekly SARS-CoV2 admissions to ICU/HDU per 100,000 population among various ethnic groups in England during the March 16, 2020 to May 1, 2022. As shown, the racial minorities have higher rates of admission to ICU/HDU during the entire COVID-19 pandemic compared to the white ethnic group.

Figure 3d:
Figure 3d:

Weekly SARS-CoV2 cases (pillars 1 and 2) per 100,000 population based on the Indices of Multiple Deprivation (IMD) from March 16, 2020 to May 1, 2022. The infection rates were higher in most derived during the entire pandemic, except during the latter part of the Delta variant and particularly the latter part of the Omicron variant surge. During the latter part of the Omicron variant surge, the infection rates of the least deprived are higher than most deprived.

Figure 3e:
Figure 3e:

Weekly SARS-CoV2 deaths per 100,000 population based on the Indices of Multiple Deprivation (IMD) from March 16, 2020 to May 1, 2022. The death rates were higher in most derived during the entire pandemic including the latter part of the Omicron variant surge than the least deprived.

SARS-CoV2 deaths among age groups in England and pre-existing conditions (Table S2)

The pre-existing conditions are present in 95.6% of COVID-19 deaths among all age groups (96.2% among those ≥60 years of age, 90.6% among 40-59 years, 82.8% among 20-39 years and 69.2% of deaths among 0-19 years of age) during the Omicron variant surge.

Vaccination rates among ethnic groups and population-based on deprivation score (IMD) as of May 1, 2022 (Table S3b)

According to the NIMS database of over 18 years, the British whites have the highest third dose vaccination rate of 76.4%, low rates of receiving two doses without a third dose (12.5%) and lowest rates of unvaccinated rate (8.9%). The population considered least deprived based on IMD decile score have the highest third dose vaccination rate (86.7%), low rates of two doses only without third dose (10.2%) and lowest unvaccinated rate (1.4%). Whereas the most deprived have lowest third dose vaccination rate (55.2%), higher rates of two doses without third dose (25.2%) and non-vaccination rate (13.9%). The racial minorities have low rates of third dose vaccination (33-55%), high rates of not receiving third dose after 2 doses (21.2%), and highest rate of non-vaccination (28.8%).

Outcomes among ≥18 years of age NIMS vaccinated population in UK (Figures 4-6, Table S3a, Tables S5a-c; Tables S6a-c, Tables S7a-c, Tables S8a-f)

The data published in UK vaccine surveillance reports (August 16, 2021-March 27, 2022) was used for the analysis. The ≥18 years of age two doses vaccinated population showed vaccine effectiveness of 17.5% (95% CI 16.5%-18.4%) for the four weeks period ending September 12, 2022. Ever since, the vaccinated with two doses and the third dose (since December 20, 2021) have negative vaccine effectiveness with the vaccinated population having a greater proportion of cases versus the unvaccinated. The UKHSA did not report third dose outcomes until December 20, 2021 in their weekly reports. In our study, we analyzed the 336,046 cases among the third booster pillar 2 population (November 27, 2021-January 12, 2022) and using the third dose weekly vaccinated population between December 26, 2021 to January 9, 2022, the best vaccine effectiveness for the third dose was 13.8%, 18.4%, and 22.2%, respectively. The two-proportions test with continuity correction (henceforth two-proportions test) showed that the all-vaccinated population have higher proportion of cases than the unvaccinated since August 23, 2021 (X2 = 11.686, df = 1, p = 0.0003149) and since the third dose reporting period of December 20, 2021 (X2= 79651, df = 1, p<0.001). Of the vaccinated populations, the vaccinated with two doses have a significantly higher proportion of cases since August 30, 2021. Since January 31, 2022, the third dose vaccinated population have significantly higher proportion of cases than the population with two doses (X2= 368.53, df = 1, p<0.001) and the unvaccinated population (X2= 55147, df = 1, p<0.001). The two-proportions test also showed that over 18 years old two doses vaccinated population have a significantly higher proportion of hospitalizations than the unvaccinated (X2= 332.3, df = 1, p<0.001) since December 6, 2021. Since January 17 2022, the vaccinated population have a significantly higher proportion of hospitalizations than the unvaccinated (X2= 14.103, df = 1, p<0.001). Since January 24, 2022, the third dose population also have a higher proportion of hospitalizations than the unvaccinated (X2= 33.446, df = 1, p<0.001). Since February 14, 2022 the third dose population have higher proportion of hospitalizations than two doses (X2= 25.946, df = 1, p<0.001) and unvaccinated (X2= 121.11, df = 1, p<0.001). The two-proportions test on deaths also showed a significantly higher proportion of deaths among vaccinated over 18 years old with two doses than unvaccinated since September 13, 2021 (X2= 7.6872, df = 1, p = 0.0028), all vaccinated population higher proportion of deaths than unvaccinated since January 10, 2022 (X2= 41.017, df = 1, p<0.001) and third dose higher (X2= 53.465, df = 1, p<0.001) than unvaccinated since January 17, 2022. Since, February 14, 2022, the vaccinated population with third dose had a higher proportion of deaths versus the vaccinated with two doses (X2= 2.8687, df = 1, p p<0.001) and unvaccinated (X2= 122.59, df = 1, p<0.001). The significantly increased proportion of cases in the vaccinated population during the Omicron variant was associated with significantly increased hospitalization and deaths among vaccinated population of ≥18 years of age with significant decreased cases, hospitalizations and deaths in unvaccinated.

Figure 4:
Figure 4:

The vaccination rates of the over 18 years of age (top left), and over 50 years of age (top right); the vaccine effectiveness of over 18 years of age (bottom left) and over 50 years of age (bottom right) during the Delta variant sure and the Omicron variant surge until March 27, 2022. The top panel shows the percentage of the population vaccinated during the vaccination program weekly (for the week ending) until March 27, 2022. The bottom panel shows vaccine effectiveness for rolling four weekly cases from August 16, 2021 until March 27, 2022 (rolling 4 weeks ending date on x-axis). The ≥50 years of age Delta variant cases vaccine effectiveness (bottom right graph), the dates are listed on x-axis. Table S3a shows detailed vaccination rates of NIMS population (all ages, over 18 years and over 50 years of age groups) and Table S3b shows the vaccination rate disparities of the ethnic groups and vaccination disparities based on the IMD score. Table S7a-c shows the vaccine effectiveness (95% CI), of ≥18 years and ≥50 years of age NIMS population including the Delta variant cases vaccine effectiveness of ≥50 years of age. The SARS-CoV2 infections among the age groups based on the vaccination status, incidence rate per 100,000 population for the specified time period included the Table S7a (≥18 yrs. of age) and Tables S7b-c (≥50 yrs. of age). Th population denominator among the age groups based on the vaccination status for the specified time period included in the Table S3a.

Figure 5a:
Figure 5a:

SARS-CoV2 cases per 100,000 population among the over 18 years of age group from August 16, 2021 to March 27, 2022. Table S8a shows that the vaccinated population (including two doses) have a significantly higher proportion of cases than the unvaccinated during the latter part of the Delta variant and initial part of Omicron variant surges. During the latter part of the Omicron variant surge, the vaccinated with the third dose have the highest proportion of infection than those vaccinated with two doses and unvaccinated. The SARS-CoV2 infections based on the vaccination status for the specified time period included the Table S6a. The population denominator for ≥18 years of age based on the vaccination status for the specified time period included in the Table S3a.

Figure 5b:
Figure 5b:

SARS-CoV2 hospitalizations per 100,000 population among the over 18 years of age group from August 16, 2021 to March 27, 2022. Table S8b shows that the vaccinated with two doses have a significantly higher proportion of hospitalizations than the unvaccinated during the initial part of the Omicron variant surge. During the latter part of the Omicron variant surge, the vaccinated with the third dose (including all vaccinated population) have the highest proportion of hospitalizations than those vaccinated with two doses and unvaccinated. The SARS-CoV2 hospitalizations based on the vaccination status for the specified time period included the Table S6b. The population denominator for ≥18 years of age based on the vaccination status for the specified time period included in the Table S3a.

Figure 5c:
Figure 5c:

SARS-CoV2 deaths per 100,000 population among the over 18 years of age group from August 16, 2021 to March 27, 2022. Table S8c shows that the vaccinated population with two doses has a significantly higher proportion of hospitalizations than the unvaccinated during the latter part of the Delta variant surge and the initial part of the Omicron variant surge. During the latter part of the Omicron variant surge, the vaccinated with the third dose (including all vaccinated population) have the highest proportion of deaths than those vaccinated with two doses and unvaccinated. The SARS-CoV2 deaths based on the vaccination status for the specified time period included the Table S6c. The population denominator for ≥18 years of age based on the vaccination status for the specified time period included in the Table S3a.

Figure 6:
Figure 6:

The percentage of SARS-CoV2 cases (left), hospitalizations (middle) and deaths (right) based on the vaccination status among all age groups (top row) over 18 years of age (middle row) and over 50 years of age (bottom row) reported from the NIMS database from August 16, 2021 to March 27, 2022. The detailed rolling four weekly changes the percentage of SARS-CoV2 cases (Table S6a), SARS-CoV2 hospitalizations (Table S6b) and SARS-CoV2 deaths (Table S6c) are shown the tables. The increased SARS-CoV2 cases among the vaccinated population in each age group during the Omicron variant surge is associated with increased SARS-CoV2 hospitalizations and SARS-CoV2 deaths in the vaccinated population. The decreased SARS-CoV2 cases among the unvaccinated population in each age group during the Omicron variant surge is associated with decreased SARS-CoV2 hospitalizations and SARS-CoV2 deaths in unvaccinated. The proportionality test results detailed in Tables S8(a-f); show that a significantly higher proportion of SARS-CoV2 cases in the vaccinated population (including the third dose) than in unvaccinated during the Omicron variant surge was associated with a significantly higher proportion of SARS-CoV2 hospitalizations in all vaccinated population (including the third dose) than the unvaccinated among ≥18 years of age and ≥50 years of age during the latter part of the Omicron variant surge. The proportionality test also shows a significantly higher proportion of deaths among the ≥18 years of age vaccinated population (including the third dose) than unvaccinated during the latter part of Omicron variant surge. The proportionality test also showed higher proportion of deaths among ≥50 years of age vaccinated with two doses than unvaccinated during the Omicron variant surge with the third dose population deaths lower than unvaccinated until March 27, 2022. The population denominator and the vaccination rates for the specified time period among the studied age groups included in the Table S3a.

The detailed analysis of ≥50 years of age vaccinated population and analysis of changing pattern of cases, hospitalizations and deaths among the various age groups are tabulated in the supplemental appendix. We also performed a comparative analysis of the two vaccination databases (NIMS and population vaccinated in England from UK coronal virus dashboard), detailed of which are included in the supplemental appendix. For the entire population of England, there were 8.4-9.0% higher proportion of unvaccinated population in NIMS database in between August 16, 2021 to March 27, 2021 that can underestimate vaccine effectiveness by about 7.5 to 12.5% (less variability in ∼4.0% range when the VE was good for two doses in February-June 2021 period) with the use of NIMS unvaccinated population. This disparity did not alter SARS-CoV2 cases per 100,000 population among the vaccinated groups (two doses, third dose and 1 dose).

DISCUSSION

There was a total of 22.07 million SARS-CoV2 cases; 848,911 hospitalizations and 175,070 deaths reported in the UK during the pandemic as of May 1, 2022. The highest percentage (51.3%) of the cases, 28.8% of total hospitalizations, 16.4% of total deaths occurred during the Omicron variant surge in 21 weeks until May 1, 2022. The Omicron variant surge was associated with lower case fatality rate and lower risk of hospitalizations than the Delta variant surge during the first twelve weeks until February 27, 2022 in our study; a similar finding was reported in a recent study for the period ending January 9, 202232. We observed significantly increased case fatality rates and the risk of hospitalizations during the latter part of Omicron variant surge, which was higher than what was observed during the Delta variant surge. We also noted an increased proportion of cases among ≥50 years age groups associated with a significantly increased proportion of hospitalizations and deaths particularly in the ≥75 years age group (80.1% of total deaths) after February 27, 2022. A similar pattern of a significantly increased proportion of SARS-CoV2 cases and hospitalizations in over 50 years old population was associated with a significantly increased proportion of deaths among ≥ 70 years old age group during the latter part of the Delta variant surge in UK33.

The ≥18 years of age NIMS population in our study showed waning of vaccine effectiveness for the two doses during the Delta variant surge (since September, 2021) with negative vaccines effectiveness for the infections during the Omicron variant surge in all the vaccinated groups including the third dose population since December 20, 2021. The two-proportions test showed a significantly higher proportion of infections in vaccinated with two doses (including all vaccinated) than the unvaccinated during the Delta variant surge (since September 2021). Additionally, the vaccinated with third dose had significantly higher infection rates versus the vaccinated with two doses and unvaccinated during the Omicron variant surge (since February 2022). This was associated with a significantly higher proportion of hospitalizations in vaccinated with two doses than unvaccinated during the Omicron variant surge (since January 2022), a higher proportion of deaths in vaccinated two doses than unvaccinated (since October 2021), and higher proportion of hospitalizations and deaths in vaccinated with the third dose than vaccinated with two doses and unvaccinated during Omicron variant surge (since February 2022).

The NIMS database also clearly shows the disparities of the vaccination rates with British white and least deprived per IMD decile score (vaccinated with highest percentages of the third dose) have the lowest infection rates, hospitalizations and deaths due to COVID-19 even before the vaccination. The ethnic minorities and the most deprived based on IMD decile score (have lowest rates of third booster vaccinations, highest rates receiving only two doses without the booster and highest rates of unvaccinated compared to British white) also had higher infection rates, hospitalizations and deaths due to COVID-19 from the beginning of the pandemic.

In our data analysis, the pre-existing conditions that were associated with 95.8 to 96.8% of deaths among 60+ years old population in England during the Omicron variant surge until May 1, 2022. The pre-existing conditions were also reported in the majority of COVID-19 deaths during the prior surges including the Delta variant surge34. The racial disparities with increased deaths due to COVID-19 among ethnic minorities compared to white British population were reported in multiple UK Office for National Statistics publications from the beginning of the COVID-19 pandemic in 2020 until recent publication on April 7,202235–38. Other studies have also shown that increased infections, hospitalizations and deaths noted among racial minorities in UK39, 40.

Based on the analysis, the vaccination groups (third dose, two doses only and unvaccinated) have heterogenous populations that have different known infection rates, hospitalizations and deaths due to COVID-19 dating back to the beginning of the pandemic way before the UK started the vaccination program in December 2020. In the light of these known variables, SARS-CoV2 cases among the compared groups for vaccine effectiveness can be adversely affected by the behavior of the population and/ or opportunity for exposure either at home or at work based on the density of population16, 41–43. Additionally, all the scientific evidence suggest that in addition to increased cases, the vast majority of hospitalizations and deaths were associated with pre-existing conditions, especially in the elderly population34, 44–46. Our study demonstrates that changes in the proportion of cases among various age groups during surges were associated with similar changes in hospitalizations (England) and deaths (England and Wales), particularly in the elderly. Based on these known variables, the vaccine effectiveness for the hospitalizations and deaths needs to be adjusted for increased cases due to behavior or exposure risk other known variables including racial ethnicity, deprivation score. Additionally, VE must be adjusted for pre-existing conditions, especially in the elderly (97.95% of the deaths during the latter part of the Omicron variant surge occurred among ≥50 years of age and 80.07% of deaths ≥75 years of age).

The disparities among SARS-CoV2 hospitalizations and deaths among the vaccinated groups have to be interpreted with great caution because the randomized controlled trials for the COVID-19 vaccines did not show demonstrable benefits to preventing hospitalization and/ or deaths and were not adequately powered to study these outcomes29–31, 47, 48. A recent randomized controlled study using the third dose of BNT162b2 vaccine did not report any benefit from severe illness, hospitalizations or deaths49. The observational studies reported good vaccine effectiveness for hospitalizations, severe illness and or deaths by reported adjustment of the variables in their statistical models for the population based on the vaccination status, but did not publish the detailed baseline characteristics (pre-existing conditions, ethnic disparities, deprivation score and their vaccination disparities) among those who were hospitalized or died due to SARS-CoV2 infection based on the vaccination status17, 18, 50, 51. A large US study (Dec 14, 2020-Aug 8, 2021) that used analysis of electronic healthcare records of individuals in their health care system (n=3,436,957 of ≥12 years of age) reported 184,041 SARS-CoV2 infections and 12,130 SARS-CoV2 hospitalizations45.

They reported significantly higher comorbidities among those with SARS-CoV2 hospitalizations; the uninfected and infected total populations have similar comorbidities45. The study did not publish the comorbidities and vaccination disparities among those who were hospitalized due to COVID-19 based on vaccination status. The study funded by a vaccine manufacturer, reported vaccine effectiveness for SARS-CoV2 infection and hospitalizations. However, they did not study if there was any mortality benefit among the vaccinated population45. In the absence of vaccine effectiveness to prevent COVID-19 infections, it is of utmost importance to develop validated models with a separate independent and comprehensive analysis all factors (age, gender, ethic/IMD score and vaccination disparities and most importantly a comprehensive analysis of all pre-existing conditions) that can independently alter the outcomes (SARS-CoV2 hospitalizations and deaths). This analysis should be independent of the risk factors in the population. After an independent analysis of these variables, a determination can be made if any intervention (vaccination or any drug therapies) was beneficial in reducing the risk of hospitalizations and/ or deaths due to SARS-COV2 infections. Difficulties in conducting clinical trials in the critical care settings during the COVID-19 pandemic were already outlined with higher chances for the occurrence of type I and type II errors due to pitfalls in appropriately matching the compared groups for all the variables that can independently affect the studies outcomes without bias52–54. Any errors in the analysis or interpretation of data in the current situation (lack of effectiveness to prevent infections) may overestimate the effectiveness (for hospitalizations and deaths) that can create a false sense of security and may harm the vaccinated population if they do not take adequate precautions to avoid infections. This is more relevant in the view of studies showing decreased vaccine effectiveness among the elderly population that is at the highest risk for increased hospitalizations and deaths18, 55.

The decreased cases among the unvaccinated population during the Omicron variant surge is probably due to protection from their prior natural infections that were already shown to give lasting immunity, which needs further study56, 57. The different vaccine effectiveness methodologies used by the Israeli (traditional vaccine effectiveness) and UK (test-negative case-control design) health officials are probably the main reasons for the discordance between the Israeli data that led to the early approvals of third dose on July 30, 2021 (Delta variant surge) and fourth dose on December 21, 2021 (Omicron variant surge) while the UK data is still showing favorable vaccine effectiveness using test-negative case-control design especially for hospitalizations and deaths which needs to be further studied14, 17, 18, 58, 59.

One limitation of our study is that it is a retrospective observational study, of publicly reported data and the generalizability of the findings is limited to the population studied in the UK. We used NIMS data population as the denominator for comparing outcomes (SARS-CoV2 cases, hospitalizations, and deaths per 100,000 population) among various age groups based on vaccination status which was also published by UKHSA in their regular weekly vaccine surveillance reports in between August 16, 2021 to March 27, 2022. Our use of unvaccinated population of NIMS databases for the vaccine effectiveness may have overestimated unvaccinated population by ∼8.4% to 9.0% and may have underestimated the vaccine effectiveness by about 7.5% to 12.5% which is not a major issue during the Omicron variant surge with waned vaccine effectiveness as outlined in the supplemental appendix. Our finding of the waning of vaccine effectiveness have validity with a recent UKHSA publication only reported protection against mild disease with the third dose vaccination during the initial stages of the Omicron variant surge and the actions of the UK authorities to recommend the fourth dose later during the Omicron surge 12, 13, 28. The prior UKHSA publications reported vaccine effectiveness for the SARS-CoV2 hospitalizations and deaths during the Delta variant surge and the recent UKHSA third dose study during the Omicron variant surge did not report outcomes of 52,369 SARS-CoV2 hospitalizations and 4,101 COVD-19 deaths among over 18 years of age that occurred in England during the study period18, 24, 28, 32, 60. The various time periods that were uses in our statistical analysis of the data are based on timing of the start of a surge and or changing pattern of increased proportion of cases, hospitalizations or deaths during the surge that were observed on plotted data. The retrospective analysis of data based on the changing patterns of outcomes yields valuable epidemiological information that can be used for public safety during the emerging pandemic as we have shown in our data analysis. Another limitation of our analysis is that we are unable to adjust the data for behavior among the compared groups that can affect the chances of contracting the disease. The changing of community testing standards in the UK since April 1, 2022 may have underestimated SARS-CoV2 cases and can overestimate CFR and RH reported in our study for that four weeks period. However, this do not invalidate the increased proportion of SARS-CoV2 cases noted among the elderly population in our study during the latter part of the Omicron variant and Delta variant surges that were associated with a significantly increased proportion of hospitalizations and deaths - a matter of significant health importance61. Our analysis identified multiple variables including ethnic disparities, deprivation score disparities and pre-existing conditions among the vaccinated populations that can affect the outcomes (SARS-CoV2 cases, hospitalizations, ICU/HDU admissions and deaths). We are unable to adjust the data specifically for the hospitalizations and deaths since we do not have access to the data (among those who were hospitalized or died) and there are no validated models that can yield unbiases data comparable to the randomized controlled trials. Furthermore, based on the vaccination disparities (ethnic and IMD score) the unadjusted data of the third dose population is expected to have better outcomes, and unadjusted data of unvaccinated and two doses without third dose population are expected to have the worse outcomes (SARS-CoV2 hospitalizations, ICU/HDU admissions and deaths). However, our findings even with the unadjusted data have public health importance as there was an increased proportion of SARS-CoV2 cases among the vaccinated population (including the third dose) that was associated with a significantly increased proportion of SARS-CoV2 hospitalizations and deaths. On the other hand, the decreasing proportion of SARS-CoV2 cases during the Omicron variant surge in the unvaccinated population is associated with a decreased proportion of SARS-CoV2 hospitalizations and deaths.

The strength of our investigation is the comprehensive analysis of nationwide real-world data of the various variables associated with SARS-CoV2 infections, hospitalizations and deaths in the UK during the entire pandemic. Our analysis also identified heterogenicity vaccinated (two doses or third dose) and unvaccinated populations that had variabilities in infection rates, hospitalizations, and death rates from the beginning of the pandemic which needed to be adjusted for vaccine effectiveness. The findings in this study are similar to recent study in Israel showing increasing breakthrough infections with waning of vaccine effectiveness in elderly population who are considered immune (mostly third dose booster population) were associated with increased severe illness and deaths during the Omicron variant surge42.

CONCLUSIONS

There was no discernable optimal vaccine effectiveness to prevent infections among the third dose ≥18 years of age population since December 20, 2021 during the initial part of the Omicron variant surge in the UK. The increased SARS CoV2 cases in the vaccinated population (including the third dose) among over 18 years of age during the Omicron variant surge were associated with significant proportion of hospitalizations and deaths; whereas the decreasing cases in the unvaccinated population were associated with decreased proportion of hospitalizations and deaths. Our data analysis identified heterogenous vaccinated (third dose, received two doses without booster) and unvaccinated populations with well-known variables that can increase the risk for hospitalizations and deaths based on ethnicity, deprivation score, and pre-existing conditions. The vaccine effectiveness for hospitalizations and deaths should be adjusted for these variables by developing validated models to avoid bias. Despite decreasing total number of cases in the UK, there was significantly increased case fatality rate and risk of hospitalizations during the latter part of the Omicron variant surge (February 28-May 1, 2022), as shown in our study. Our study attribute this phenomenon to a significantly increased proportion of cases among ≥50 years of age that was associated with a significantly increased risk of hospitalizations and deaths among ≥75 years of age. This underscores the importance of the public health measures directed at uniform screening protocols, and protective measures to prevent infection among elderly vaccinated and unvaccinated populations.

Footnotes

  • Conflicts of interests: The authors have no conflict of interest or financial relationships relevant to the submitted review to disclose.

  • Authorship: This manuscript was initially drafted by the first author, and approved by all authors. VRE analyzed the data; VKP, DN, RR, KRM and ASN verified all the data and the submitted data was reviewed by all authors. All authors have access to the complete data that was analyzed for this manuscript.

  • Funding: None; The author(s) received no financial support for the research, authorship, and/or publication of this article

  • IRB approval: Not required.

  • We addressed the following in the current revision 1)We used NIMS data population as the denominator for comparing outcomes (SARS-CoV2 cases, hospitalizations, and deaths per 100,000 population) among various age groups based on vaccination status which was also published by UKHSA in their regular weekly vaccine surveillance reports in between August 16, 2021 to March 27, 2022. Our use of unvaccinated population of NIMS databases for the vaccine effectiveness may have overestimated unvaccinated population by ~8.4% to 9.0% and may have underestimated the vaccine effectiveness by about 7.5% to 12.5% which is not a major issue during the Omicron variant surge with waned vaccine effectiveness as outlined in the supplemental appendix through our comparative validation of both the database denominators. 2)We proposed suggestions for how the validation methods can be developed for evaluation of the vaccine effectiveness for the SARS-CoV2 hospitalizations and deaths.

REFERENCES

  1. 1.↵
    UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England: Omicron VOC-21NOV-01 (B.1.1.529) update on cases, S gene target failure and risk assessment. Published online 2021. Accessed December 7, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1039644/Omicron_SGTF_case_update_FINAL.pdf
  2. 2.
    UK Health Security Agency (UKHSA). Research and analysis Variants: distribution of case data, 3 December 2021. Published online 2021. Accessed May 5, 2022. https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-3-december-2021
  3. 3.↵
    World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Published online 2021. Accessed November 25, 2021. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
  4. 4.↵
    UK Health Security Agency (UKHSA). Research and analysis Variants: distribution of case data, 23 December 2021 . Published online 2021. Accessed December 22, 2021. https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-23-december-2021
  5. 5.↵
    UK Health Security Agency (UKHSA). Research and analysis Variants: distribution of case data, 7 January 2022 . Published online 2022. Accessed January 6, 2022. https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-7-january-2022
  6. 6.↵
    GOV.UK Coronavirus (COVID-19) in the UK. Coronavirus (COVID-19) in the UK. Published online 2022. Accessed April 22, 2022. https://coronavirus.data.gov.uk/
  7. 7.↵
    UK Health Security Agency (UKHSA). Research and analysis Variants: distribution of case data, 6 May 2022 . Published online 2022. Accessed May 5, 2022. https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-6-may-2022
  8. 8.↵
    UK Health Security Agency (UKHSA). National flu and COVID-19 surveillance reports: 2021 to 2022 season. Published online 2022. Accessed May 7, 2022. https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2021-to-2022-season
  9. 9.↵
    Department of Health & Social Care. The JCVI is advising that people with severely weakened immune systems should have a third vaccine dose as part of their primary COVID-19 vaccination schedule. Published online 2021. Accessed August 31, 2021. https://www.gov.uk/government/news/jcvi-issues-advice-on-third-dose-vaccination-for-severely-immunosuppressed
  10. 10.↵
    Department of Health & Social Care. The Joint Committee on Vaccination and Immunisation (JCVI) has updated its advice on the COVID-19 vaccine booster programme. Published online 2021. Accessed September 13, 2022. https://www.gov.uk/government/news/jcvi-issues-updated-advice-on-covid-19-booster-vaccination
  11. 11.↵
    Department of Health & Social Care. JCVI advice on COVID-19 booster vaccines for those aged 18 to 39 and a second dose for ages 12 to 151: Following the emergence of the Omicron variant, including confirmed cases in the UK, JCVI has urgently reviewed vaccine response measures. Published online 2021. Accessed November 28, 2021. https://www.gov.uk/government/news/jcvi-advice-on-covid-19-booster-vaccines-for-those-aged-18-to-39-and-a-second-dose-for-ages-12-to-15
  12. 12.↵
    Independent. Britons to get fourth Covid-19 vaccination, says Boris Johnson. Published online 2022. Accessed March 18, 2022. https://www.independent.co.uk/news/uk/politics/boris-johnson-covid-coronavirus-vaccination-b2039679.html
  13. 13.↵
    13. UK Parliament: House of Commons Library. Coronavirus: Covid-19 booster vaccines frequently asked questions. Published online 2022. Accessed April 12, 2022. https://commonslibrary.parliament.uk/research-briefings/cbp-9332/
  14. 14.↵
    Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. New England Journal of Medicine. Published online October 27, 2021. doi:10.1056/NEJMoa2114228
    OpenUrlCrossRefPubMed
  15. 15.
    Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. New England Journal of Medicine. 2021;385(24):e83. doi:10.1056/NEJMoa2114114
    OpenUrlCrossRefPubMed
  16. 16.↵
    Baden LR, el Sahly HM, Essink B, et al. Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. New England Journal of Medicine. 2021;385(26):2485–2487. doi:10.1056/NEJMc2115597
    OpenUrlCrossRef
  17. 17.↵
    Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine. Published online July 21, 2021. doi:10.1056/NEJMoa2108891
    OpenUrlCrossRefPubMed
  18. 18.↵
    Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. New England Journal of Medicine. 2022;386(4):340–350. doi:10.1056/NEJMoa2115481
    OpenUrlCrossRef
  19. 19.↵
    Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 17. Published online June 25, 2021. Accessed June 24, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1001354/Variants_of_Concern_VOC_Technical_Briefing_17.pdf
  20. 20.
    Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 23. Published online September 17, 2021. Accessed September 16, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1018547/Technical_Briefing_23_21_09_16.pdf
  21. 21.↵
    Emani VR, Reddy R, Goswami S. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine. 2021;385(25):e92. doi:10.1056/NEJMc2113090
    OpenUrlCrossRef
  22. 22.↵
    UK Health Security Agency. COVID-19 vaccine weekly surveillance reports (weeks 39 to 17, 2021 to 2022). Published online 2022. Accessed May 6, 2022. https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports
  23. 23.↵
    Public Health England. National flu and COVID-19 surveillance reports. Published online 2021. Accessed October 15, 2021. https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports
  24. 24.↵
    National Health Service (NHS) England. COVID-19 Hospital Activity. Accessed October 22, 2021. https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/
  25. 25.↵
    Deaths registered weekly in England and Wales provisional. Deaths registered weekly in England and Wales, provisional. Published online 2022. Accessed May 3, 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/weeklyprovisionalfiguresondeathsregisteredinenglandandwales
  26. 26.↵
    National Health Services (NHS) Enhland. COVID-19 Weekly Total Deaths Archive. Published online 2022. Accessed April 27, 2022. https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-daily-deaths/weekly-total-archive/
  27. 27.↵
    Public Health England. Investigation of SARS-CoV-2 variants of concern: technical briefings:Technical briefing documents on novel SARS-CoV-2 variants. Published online 2021. https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201
  28. 28.↵
    Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine. 2022;386(16):1532–1546. doi:10.1056/NEJMoa2119451
    OpenUrlCrossRefPubMed
  29. 29.↵
    Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269). doi:10.1016/S0140-6736(20)32661-1
    OpenUrlCrossRefPubMed
  30. 30.
    Baden LR, el Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021;384(5). doi:10.1056/NEJMoa2035389
    OpenUrlCrossRefPubMed
  31. 31.↵
    Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020;383(27). doi:10.1056/NEJMoa2034577
    OpenUrlCrossRefPubMed
  32. 32.↵
    Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet. 2022;399(10332):1303–1312. doi:10.1016/S0140-6736(22)00462-7
    OpenUrlCrossRefPubMed
  33. 33.↵
    Emani VR, Nakka AS, Goswami KK, et al. Changing Dynamics of SARS-CoV-2. B.1.617.2 (Delta Variant) Outbreak in the United Kingdom: Shifting of SARS-CoV-2 Infections from Younger to Elderly Populations with Increasing Hospitalizations and Mortality Among Elderly. J Infect Dis Ther. 2022;10(3). doi:10.4172/2332-0877.1000497
    OpenUrlCrossRef
  34. 34.↵
    Emani VR, Reddy R, Goswami KK, et al. Preexisting conditions among the SARS-CoV2 deaths during the SARS-CoV2 B.1.617.2 (Delta variant) outbreak in the United Kingdom. Journal of Global Antimicrobial Resistance. Published online February 2022. doi:10.1016/j.jgar.2022.02.014
    OpenUrlCrossRef
  35. 35.↵
    UK Office for National Statistics. Coronavirus (COVID-19) related deaths by ethnic group, England and Wales: 2 March 2020 to 15 May 2020. Published online 2020. Accessed June 18, 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/coronaviruscovid19relateddeathsbyethnicgroupenglandandwales/2march2020to15may2020
  36. 36.
    UK Office for National Statistics. Updating ethnic contrasts in deaths involving the coronavirus (COVID-19), England: 24 January 2020 to 31 March 2021. Published online 2021. Accessed May 25, 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/updatingethniccontrastsindeathsinvolvingthecoronaviruscovid19englandandwales/24january2020to31march2021
  37. 37.
    UK Office for National Statistics. Updating ethnic contrasts in deaths involving the coronavirus (COVID-19), England: 8 December 2020 to 1 December 2021. Published online 2022. Accessed January 25, 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/updatingethniccontrastsindeathsinvolvingthecoronaviruscovid19englandandwales/8december2020to1december2021
  38. 38.↵
    UK Office for National Statistics. Updating ethnic contrasts in deaths involving the coronavirus (COVID-19), England: 10 January 2022 to 16 February 2022. Published online 2022. Accessed April 6, 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/updatingethniccontrastsindeathsinvolvingthecoronaviruscovid19englandandwales/10january2022to16february2022
  39. 39.↵
    Nafilyan V, Islam N, Mathur R, et al. Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England. European Journal of Epidemiology. 2021;36(6):605–617. doi:10.1007/s10654-021-00765-1
    OpenUrlCrossRefPubMed
  40. 40.↵
    Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. The Lancet. 2021;397(10286):1711–1724. doi:10.1016/S0140-6736(21)00634-6
    OpenUrlCrossRefPubMed
  41. 41.↵
    Sutton J, Shahtahmassebi G, Ribeiro H v., Hanley QS. Population density and spreading of COVID-19 in England and Wales. PLOS ONE. 2022;17(3):e0261725. doi:10.1371/journal.pone.0261725
    OpenUrlCrossRef
  42. 42.↵
    Emani VR, Nandanoor D, Reddy R, et al. SARS-CoV2 Breakthrough Infections in Elderly Third Booster and Vaccinated Population Considered Vaccine Immune During Omicron (B.1.1.529)Variant Surge in Israel. Current Trends in Biotechnology and Pharmacy. 2022;16(2):235–252. doi:10.5530/ctbp.2022.2.22
    OpenUrlCrossRef
  43. 43.↵
    Keehner J, Horton LE, Binkin NJ, et al. Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. New England Journal of Medicine. Published online September 1, 2021. doi:10.1056/NEJMc2112981
    OpenUrlCrossRefPubMed
  44. 44.↵
    O’Hearn M, Liu J, Cudhea F, Micha R, Mozaffarian D. Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis. J Am Heart Assoc. 2021;10(5). doi:10.1161/JAHA.120.019259
    OpenUrlCrossRefPubMed
  45. 45.↵
    Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. The Lancet. 2021;398(10309):1407–1416. doi:10.1016/S0140-6736(21)02183-8
    OpenUrlCrossRefPubMed
  46. 46.↵
    Wei W, Sivapalasingam S, Mellis S, Geba GP, Jalbert JJ. A Retrospective Study of COVID-19-Related Urgent Medical Visits and Hospitalizations After Outpatient COVID-19 Diagnosis in the US. Advances in Therapy. 2021;38(6):3185–3202. doi:10.1007/s12325-021-01742-6
    OpenUrlCrossRef
  47. 47.↵
    Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet. 2021;397(10277). doi:10.1016/S0140-6736(21)00432-3
    OpenUrlCrossRefPubMed
  48. 48.↵
    Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine. 2021;385(19):1761–1773. doi:10.1056/NEJMoa2110345
    OpenUrlCrossRefPubMed
  49. 49.↵
    Moreira ED, Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. New England Journal of Medicine. 2022;386(20):1910–1921. doi:10.1056/NEJMoa2200674
    OpenUrlCrossRef
  50. 50.↵
    Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet. 2021;397(10287). doi:10.1016/S0140-6736(21)00947-8
    OpenUrlCrossRefPubMed
  51. 51.↵
    Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. New England Journal of Medicine. Published online September 15, 2021. doi:10.1056/NEJMoa2114255
    OpenUrlCrossRefPubMed
  52. 52.↵
    Frieden TR. Evidence for Health Decision Making — Beyond Randomized, Controlled Trials. New England Journal of Medicine. 2017;377(5):465–475. doi:10.1056/NEJMra1614394
    OpenUrlCrossRefPubMed
  53. 53.
    Santacruz CA, Pereira AJ, Celis E, Vincent JL. Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review. Critical Care Medicine. 2019;47(12):1680–1691. doi:10.1097/CCM.0000000000004000
    OpenUrlCrossRef
  54. 54.↵
    Emani VR, Goswami S, Nandanoor D, Emani SR, Reddy NK, Reddy R. Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies—need for data validation of the completed trials and to improve ongoing and future randomised trial designs. International Journal of Antimicrobial Agents. 2021;57(1). doi:10.1016/j.ijantimicag.2020.106222
    OpenUrlCrossRef
  55. 55.↵
    Ioannou GN, Locke ER, O’Hare AM, et al. COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System. Annals of Internal Medicine. Published online December 21, 2021. doi:10.7326/M21-3256
    OpenUrlCrossRef
  56. 56.↵
    Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. The Lancet Infectious Diseases. 2022;22(1):12–14. doi:10.1016/S1473-3099(21)00676-9
    OpenUrlCrossRef
  57. 57.↵
    Jeffery-Smith A, Rowland TAJ, Patel M, et al. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. The Lancet Healthy Longevity. 2021;2(12):e811–e819. doi:10.1016/S2666-7568(21)00253-1
    OpenUrlCrossRef
  58. 58.↵
    Israel Ministry of Health. Administration of 4th Vaccine was Approved for People Aged 60 And Older and for Medical Teams. Published online 2022. Accessed January 2, 2022. https://www.gov.il/en/departments/news/02012022-04
  59. 59.↵
    Israel Ministry of Health. The Vaccination Advisory Committee Presented Data and Recommended the Administration of a Third Dose to Older Adults. Accessed July 29, 2021. https://www.gov.il/en/departments/news/29072021-04
  60. 60.↵
    NHS England and NHS Improvement. COVID-19 Weekly Total Deaths Archive. Published online 2021. Accessed October 20, 2021. https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-daily-deaths/weekly-total-archive/
  61. 61.↵
    UK Health Security Agency (UKHSA). Changes to COVID-19 testing in England from 1 April. Published online 2022. Accessed March 29, 2022. https://www.gov.uk/government/news/changes-to-covid-19-testing-in-england-from-1-april
Back to top
Posted July 11, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Increasing SARS-CoV2 cases, hospitalizations and deaths among the vaccinated elderly populations during the Omicron (B.1.1.529) variant surge in UK
Venkata R. Emani, Vivek K. Pallipuram, Kartik K. Goswami, Kailash R. Maddula, Raghunath Reddy, Abirath S. Nakka, Sravya Panga, Nikhila K. Reddy, Nidhi K. Reddy, Dheeraj Nandanoor, Sanjeev Goswami
medRxiv 2022.06.28.22276926; doi: https://doi.org/10.1101/2022.06.28.22276926
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area